Journal of the American Academy of Dermatology
Volume 63, Issue 4 , Pages 642-646, October 2010

Treatment of actinic cheilitis with the Er:YAG laser

  • Paul Armenores, MBBS

      Affiliations

    • Flinders Medical Centre, Bedford Park, Adelaide, Australia
    • Corresponding Author InformationCorrespondence to: Paul Armenores, Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia, 5042, Australia.
  • ,
  • Craig L. James, FRCPA

      Affiliations

    • Adelaide Pathology Partners, Adelaide, Australia
  • ,
  • Patrick C. Walker, FACD

      Affiliations

    • Repatriation General Hospital, Daw Park, Adelaide, Australia
  • ,
  • Shyamala C. Huilgol, FACD

      Affiliations

    • Adelaide Skin and Eye Centre, Kent Town, Adelaide, Australia

Background

Actinic cheilitis is a common condition with the potential to develop into squamous cell carcinoma. Current treatments have varying cure rates and complications. The role of the erbium:yttrium-aluminum-garnet (Er:YAG) laser in the treatment of actinic cheilitis has not been widely published, despite offering theoretical advantages over current treatment modalities.

Objective

To evaluate the outcome of a series of patients treated with the Er:YAG laser for actinic cheilitis.

Methods

This was a retrospective, interventional, nonrandomized, sequential case series set in a tertiary referral, dermatologic surgery unit. Ninety-nine consecutive patients with actinic cheilitis treated with the Er:YAG laser between January 2001 and June 2008 underwent a case note review, of which 77 went on to a structured telephone interview. The main outcome measures were a subjective improvement in lip symptoms related to actinic cheilitis and objective improvement in the lips at routine follow-up.

Results

Mean time to interview follow-up was 65.7 months. Of those interviewed, 92.2% believed there had been an improvement in the cosmetic appearance of their lips; one hundred percent believed the function of their lips had improved or remained unchanged; and 84.8% remained completely disease free at the time of follow-up. The majority of patients (93.5%) were satisfied with the laser treatment. Scarring as a direct result of the laser occurred in 5.1% of patients.

Limitations

Retrospective nature of data collection; inability to interview all patients who underwent treatment.

Conclusion

The Er:YAG laser is a successful modality for the treatment of actinic cheilitis with good functional and cosmetic results and only a small risk of long-term scarring. It should be considered as a first-line treatment for the disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding sources: None.

 Conflicts of interest: None declared.

 Reprints not available from the authors.

PII: S0190-9622(09)02109-4

doi:10.1016/j.jaad.2009.11.586

Journal of the American Academy of Dermatology
Volume 63, Issue 4 , Pages 642-646, October 2010